SYMPHONY-PE Analysis Shows Early Thrombectomy Linked to Better Outcomes

June 19, 2026—Imperative Care announced findings from a post hoc analysis of the SYMPHONY-PE trial that suggest that mechanical thrombectomy performed within 12 hours of diagnosis may be associated with greater hemodynamic and right ventricular recovery in patients with intermediate-risk pulmonary embolism (PE) compared with treatment performed later.

ThruFlo Secures Funding to Advance Development of Its Flow Diverter for Bifurcation Aneurysms

June 16, 2026—ThruFlo Endovascular, Inc., a neuroendovascular medical device company, announced the completion of seed funding to accelerate development of its bifurcated flow diverter platform.

CEA and CAS Outcomes Compared in Real-World Study of Asymptomatic Carotid Stenosis

June 15, 2026—The Society for Vascular Surgery (SVS) announced findings from a new study showing lower long-term stroke and stroke or death rates with carotid endarterectomy (CEA) compared with carotid artery stenting (CAS) in patients with asymptomatic carotid stenosis.

Thrombolex Appoints Michael Tutera as Chief Executive Officer

June 15, 2026—Thrombolex, Inc., developer of the Bashir endovascular catheter platform for the pharmacomechanical lysis treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced that the Board of Directors has appointed Michael Tutera as Chief Executive Officer.

Penumbra’s Thunderbolt CAVT Platform for Stroke Gains CE Mark Approval 

June 15, 2026—Penumbra, Inc. announced CE Mark approval for the company’s Thunderbolt computer-assisted vacuum thrombectomy (CAVT) platform to treat acute ischemic stroke globally.

Medtronic Completes Acquisition of Scientia Vascular

June 12, 2026—Medtronic announced it has completed its acquisition of Scientia Vascular, a privately held developer of access products for the treatment of complex neurovascular conditions.

Spectrum Vascular Acquires Piccolo Medical

June 12, 2026—Spectrum Vascular announced the acquisition of Piccolo Medical, a developer of catheter guidance products.

WaveClear Licenses Resolution Thrombectomy Technology to Two Chinese Companies

June 12, 2026—WaveClear Vascular, developer of the Resolution cavitation system, announced that it has entered into licensing agreements with two Chinese medical device companies for Resolution, a 6-F catheter-based thrombectomy platform for the treatment of peripheral vascular disease.